Cysteamine cream and tranexamic acid mesotherapy demonstrated similar efficacy but yielded different safety results when being compared as a treatment for melasma, according to a recently published study.
Lasers typically used for tattoo removal are on the rise as a possible treatment for melasma, with the novel 730 nm picosecond laser (PicoWay, Candela) being the most recently studied device which showed to be safe and effective for treating benign pigmented lesions.
The importance of blocking visible light in the treatment of pigmentary disorders is becoming clearer. One expert says photoprotection in patients with pigmentary conditions is a therapeutic cornerstone.
Effective treatment first requires accurate diagnosis, one expert says. He offers tips to distinguish melasma from other disorders and suggests some patients may need to be checked for diabetes and metabolic syndrome if they exhibit certain presentations.
In a study of more than 200 men and women, clinicians scored patients’ pigmentation taking into account how much of the face was impacted and compared scores to patients’ responses to the Skindex-16 questionnaire.
Researchers examined a group of adult women diagnosed with melasma who applied a traditional medicinal product on one side of their face and 4% hydroquinone on the other side.
In patients with melasma, an in vivo imaging technique can effectively diagnose the condition as well as measure response to laser treatment, a recent study indicates.
Stem cell factor, a growth factor critical for melanocyte survival, may play an important role in the development of benign and malignant skin hyperpigmentation disorders.
Oral tranexamic acid combined with low fluence 1064 nm Q-switched Nd: YAG laser is an effective and safe melasma treatment, with outcomes that are better than oral tranexamic acid alone, according to a recent study.
Chemical peels offer important advantages for treating melasma. Researchers offer insights from a review of recent advances in chemical peel treatments in melasma and acne.